This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 7
  • /
  • Advaxis Inc, and Biosight Ltd. to merge and trade ...
News

Advaxis Inc, and Biosight Ltd. to merge and trade as Biosight Therapeutics.

Read time: 1 mins
Published:7th Jul 2021
Advaxis, Inc. and Biosight Ltd. a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.

The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine (BST-236). The combined company is expected to have approximately $50 million in cash, cash equivalents and marketable securities at closing. Following the closing, which is expected to occur in the second half of 2021, Advaxis will be renamed Biosight Therapeutics.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.